CN112480167B - 水胺硫磷半抗原、人工抗原和抗体及其制备方法和应用 - Google Patents
水胺硫磷半抗原、人工抗原和抗体及其制备方法和应用 Download PDFInfo
- Publication number
- CN112480167B CN112480167B CN202011285140.XA CN202011285140A CN112480167B CN 112480167 B CN112480167 B CN 112480167B CN 202011285140 A CN202011285140 A CN 202011285140A CN 112480167 B CN112480167 B CN 112480167B
- Authority
- CN
- China
- Prior art keywords
- isocarbophos
- hapten
- nitro
- reaction
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YFVOXLJXJBQDEF-UHFFFAOYSA-N isocarbophos Chemical compound COP(N)(=S)OC1=CC=CC=C1C(=O)OC(C)C YFVOXLJXJBQDEF-UHFFFAOYSA-N 0.000 title claims abstract description 105
- 239000000427 antigen Substances 0.000 title claims abstract description 26
- 102000036639 antigens Human genes 0.000 title claims abstract description 26
- 108091007433 antigens Proteins 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 230000003053 immunization Effects 0.000 claims abstract description 12
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 11
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- 230000008878 coupling Effects 0.000 claims abstract description 4
- 238000010168 coupling process Methods 0.000 claims abstract description 4
- 238000005859 coupling reaction Methods 0.000 claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 229940098773 bovine serum albumin Drugs 0.000 claims description 9
- 239000012074 organic phase Substances 0.000 claims description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 8
- -1 nitro isocarbophos Chemical compound 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 7
- 229940092253 ovalbumin Drugs 0.000 claims description 7
- UKWUOTZGXIZAJC-UHFFFAOYSA-N 4-nitrosalicylic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1O UKWUOTZGXIZAJC-UHFFFAOYSA-N 0.000 claims description 6
- 108010058846 Ovalbumin Proteins 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 3
- JJGSZKDBNXEJMI-UHFFFAOYSA-N P(=S)(OC(C)C)(O)O.[N+](=O)([O-])C=1C=C(C(C(=O)O)=CC1)O Chemical compound P(=S)(OC(C)C)(O)O.[N+](=O)([O-])C=1C=C(C(C(=O)O)=CC1)O JJGSZKDBNXEJMI-UHFFFAOYSA-N 0.000 claims description 3
- 238000005886 esterification reaction Methods 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000006722 reduction reaction Methods 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 230000001502 supplementing effect Effects 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 108060003552 hemocyanin Proteins 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 17
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 239000002917 insecticide Substances 0.000 abstract description 5
- 238000003018 immunoassay Methods 0.000 abstract description 4
- 230000028993 immune response Effects 0.000 abstract description 3
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000002649 immunization Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004303 peritoneum Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 239000005944 Chlorpyrifos Substances 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- PNVJTZOFSHSLTO-UHFFFAOYSA-N Fenthion Chemical compound COP(=S)(OC)OC1=CC=C(SC)C(C)=C1 PNVJTZOFSHSLTO-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- MUUGCDGGIVCSDT-UHFFFAOYSA-N [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O Chemical compound [NH4+].[NH4+].[O-]S([O-])(=O)=O.CCCCCCCC(O)=O MUUGCDGGIVCSDT-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SBPBAQFWLVIOKP-UHFFFAOYSA-N chlorpyrifos Chemical compound CCOP(=S)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl SBPBAQFWLVIOKP-UHFFFAOYSA-N 0.000 description 1
- HRBKVYFZANMGRE-UHFFFAOYSA-N chlorpyrifos-methyl Chemical compound COP(=S)(OC)OC1=NC(Cl)=C(Cl)C=C1Cl HRBKVYFZANMGRE-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003986 organophosphate insecticide Substances 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- RLBIQVVOMOPOHC-UHFFFAOYSA-N parathion-methyl Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C=C1 RLBIQVVOMOPOHC-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000447 pesticide residue Substances 0.000 description 1
- BULVZWIRKLYCBC-UHFFFAOYSA-N phorate Chemical compound CCOP(=S)(OCC)SCSCC BULVZWIRKLYCBC-UHFFFAOYSA-N 0.000 description 1
- ATROHALUCMTWTB-OWBHPGMISA-N phoxim Chemical compound CCOP(=S)(OCC)O\N=C(\C#N)C1=CC=CC=C1 ATROHALUCMTWTB-OWBHPGMISA-N 0.000 description 1
- 229950001664 phoxim Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- QYMMJNLHFKGANY-UHFFFAOYSA-N profenofos Chemical compound CCCSP(=O)(OCC)OC1=CC=C(Br)C=C1Cl QYMMJNLHFKGANY-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2430/00—Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
- G01N2430/10—Insecticides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了水胺硫磷半抗原、人工抗原和抗体及其制备方法和应用,本发明提供的水胺硫磷半抗原既最大程度保留了水胺硫磷的特征结构,使得水胺硫磷半抗原的免疫原性明显增强,又具有可以与载体蛋白发生偶联的氨基;用水胺硫磷半抗原与载体蛋白偶联后得到的水胺硫磷人工抗原去免疫动物,更有利于刺激动物免疫应答产生特异性更强、灵敏度更高的抗体,经检测水胺硫磷抗体的灵敏度可达0.03μg/L,与其他有机磷杀虫剂的交叉反应率低,为后续建立水胺硫磷的各种免疫分析方法提供了基础。
Description
技术领域
本发明属于食品安全检测领域。更具体地,本发明涉及水胺硫磷半抗原、人工抗原和抗体及其制备方法和应用。
背景技术
水胺硫磷是一种速效广谱的有机磷杀虫剂,主要用于防治果树、水稻和棉花害虫,由于具有杀虫效率高、碱性条件下易分解等优点,一度成为农业生产中的主要杀虫剂之一。但水胺硫磷的滥用,不仅会造成农药在环境中残留,还可通过食物链的富集作用使动物和人中毒,进而对人体的代谢平衡产生影响,尤其是对儿童神经系统的正常发育产生更为严重的影响。我国国家标准GB 2763规定蔬菜及部分水果中水胺硫磷的最大残留限量为0.05mg/kg,因此,建立水胺硫磷残留快速检测技术,对于保障食品安全和人类健康、减少环境污染具有重要意义。
目前,国内外检测水胺硫磷主要采用气相色谱法、气相色谱-质谱法和液相色谱串联质谱法等分析方法,存在样品前处理繁琐、检测时间长、仪器贵重等缺点,所以在我国无法得到广泛应用,并且不符合现场检测“在短时间内低成本对大量样品进行准确检测和筛选”的要求。而免疫学检测分析技术以其高灵敏、特异性高、快速、操作简便等优点在药物残留检测领域已被广泛应用,比起仪器等检验方法有很多优势。所以免疫分析为水胺硫磷残留研究提供了一条新的分析检测方法。
在建立免疫学检测方法并应用该检测方法检测水胺硫磷残留量时,关键技术在于能够获取到特异性强、灵敏度高的抗体,而要实现这一目标,前提条件就是得合成、制备出合适的水胺硫磷半抗原。
发明内容
针对现有技术中存在的不足之处,本发明提供一种能最大程度保留水胺硫磷的特征结构,又具有一定长度连接臂的半抗原以及这种半抗原的制备方法;以此半抗原制备的人工抗原、检测灵敏度高和特异性强的抗体;以及此半抗原的应用。
为了实现本发明的目的,第一方面,本发明提供一种水胺硫磷半抗原,其具有如下结构式:
本发明提供的水胺硫磷半抗原在水胺硫磷的分子结构上引入氨基活性基团,从而可以与载体蛋白进行偶联得到人工抗原用于免疫;该水胺硫磷半抗原保留了水胺硫磷的所有特征基团,最小改变水胺硫磷原有结构特征,同时与载体蛋白偶联后,突出的是水胺硫磷本身独有的结构,为后续刺激动物免疫应答产生特异性更强、灵敏度更高的抗体奠定基础。
第二方面,本发明提供上述水胺硫磷半抗原的制备方法,其包括如下步骤:
1)在催化剂存在下,将4-硝基水杨酸和异丙醇进行酯化反应,纯化后得到4-硝基水杨酸异丙酯;
2)在催化剂存在和碱性条件下,将4-硝基水杨酸异丙酯和O-甲基硫代磷酰二氯进行缩合反应,纯化后得到4-硝基水杨酸异丙酯硫磷;
3)将4-硝基水杨酸异丙酯硫磷和氨气进行氨化反应,纯化后得到硝基水胺硫磷;
4)在催化剂存在下,将硝基水胺硫磷和氢气进行还原反应,纯化后得到水胺硫磷半抗原。
进一步地,上述步骤1)包括如下步骤:取4-硝基水杨酸1.83g,加入20mL异丙醇溶解,充分搅拌,加入0.5mL浓硫酸,室温搅拌3h,停止反应,加入200mL水,再加入100mL乙酸乙酯萃取,有机相加100mL水震荡、洗涤,浓缩蒸干,得到4-硝基水杨酸异丙酯。
进一步地,上述步骤2)包括如下步骤:在4-硝基水杨酸异丙酯中直接加入80mL二氯甲烷溶解,加入1.64g O-甲基硫代磷酰二氯,充分搅拌,加入3mL三乙胺,室温搅拌4h,停止反应,加入100mL水,补加100mL二氯甲烷萃取,有机相加60mL饱和食盐水震荡、洗涤,浓缩蒸干,上硅胶柱,用二氯甲烷和甲醇体积比为10:1的混合溶剂洗脱分离,得到4-硝基水杨酸异丙酯硫磷。
进一步地,上述步骤3)包括如下步骤:在4-硝基水杨酸异丙酯硫磷中直接加入100mL二氯乙烷溶解,在搅拌下通入氨气,室温反应2h,停止反应,加水50mL×3,洗涤3次,有机相浓缩蒸干,得到硝基水胺硫。
进一步地,上述步骤4)包括如下步骤:在硝基水胺硫磷中直接加入100mL甲醇溶解,加入0.5g润湿的钯-碳,排尽空气,通入氢气,室温搅拌2h,停止反应,抽滤,蒸干,上硅胶柱,用二氯甲烷和甲醇体积比为5:1的混合溶剂洗脱分离,得到水胺硫磷半抗原。
本发明根据水胺硫磷的结构特点,以4-硝基水杨酸为起始原料,经过羧基酯化、与O-甲基硫代磷酰二氯缩合、氨化、还原等一系列反应,合成带有氨基的间隔臂,使用的原料易得,反应操作较为简单,反应条件易于控制,制备的水胺硫磷半抗原的纯度和收率较高。
第三方面,本发明提供一种水胺硫磷人工抗原,其是载体蛋白和上述水胺硫磷半抗原偶联得到的偶联物。所述水胺硫磷人工抗原可以作为免疫原,也可以作为包被原。
进一步地,所述载体蛋白为牛血清白蛋白、卵清蛋白、人血清白蛋白或血蓝蛋白;优选牛血清白蛋白、卵清蛋白。
更具体的如:水胺硫磷半抗原-牛血清白蛋白(BSA)形成的免疫原;水胺硫磷半抗原-卵清蛋白(OVA)形成的包被原。
水胺硫磷半抗原分子仅具有免疫反应性,而不具有免疫原性。因此,为了赋予水胺硫磷半抗原分子以免疫原性,还需要将该水胺硫磷半抗原分子与合适的载体蛋白分子偶联、结合在一起,由此产生既具有免疫反应性又具有免疫原性的水胺硫磷人工抗原。
第四方面,本发明提供一种水胺硫磷抗体,它是由上述水胺硫磷人工抗原经动物免疫得到,其能与水胺硫磷发生特异性免疫反应。
进一步地,所述水胺硫磷抗体为单克隆抗体或多克隆抗体。另外,对于所述水胺硫磷抗体,可以采用本领域常规方法来进行制备。
在一个具体的实施方案中,所述水胺硫磷抗体为特异性针对上述水胺硫磷半抗原的水胺硫磷人工抗原的鼠源单克隆抗体。
采用本发明的水胺硫磷人工抗原得到的水胺硫磷抗体的效价、特异性、亲和力都较好,与其他有机磷杀虫剂的交叉反应率低。
第五方面,本发明提供上述水胺硫磷抗体在检测水胺硫磷残留中的应用。
本发明通过水胺硫磷人工抗原诱导免疫动物产生抗体,从而用于水胺硫磷免疫检测分析中。
所述的水胺硫磷免疫检测包括但不限于水胺硫磷ELISA试剂盒、水胺硫磷胶体金试纸条、水胺硫磷时间分辨荧光试纸条。
借由上述技术方案,本发明至少具有如下优点及有益效果:
本发明提供的水胺硫磷半抗原既最大程度保留了水胺硫磷的特征结构,使得水胺硫磷半抗原的免疫原性明显增强,又具有可以与载体蛋白发生偶联的氨基;用水胺硫磷半抗原与载体蛋白偶联后得到的水胺硫磷人工抗原去免疫动物,更有利于刺激动物免疫应答产生特异性更强、灵敏度更高的抗体,为后续建立水胺硫磷的各种免疫分析方法提供基础。
本发明中水胺硫磷半抗原的制备方法,使用的原料易得,反应操作较为简单,反应条件易于控制,制备的水胺硫磷半抗原的纯度和收率较高。
采用本发明的水胺硫磷人工抗原得到的水胺硫磷抗体的效价、特异性、亲和力都较好,灵敏度可达到0.03μg/L,与其他有机磷杀虫剂的交叉反应率低。
附图说明
图1是本发明水胺硫磷半抗原的合成路线
具体实施方式
下面结合具体实施例进一步详细说明本发明,但实施例仅是本发明的优选实施方式,并不是对本发明的限定。
实施例1
一种水胺硫磷半抗原的制备方法,其包括如下步骤:
1)取4-硝基水杨酸1.83g,加入20mL异丙醇溶解,充分搅拌,加入0.5mL浓硫酸,室温搅拌3h,停止反应,加入200mL水,再加入100mL乙酸乙酯萃取,有机相加100mL水震荡、洗涤,浓缩蒸干,得到4-硝基水杨酸异丙酯;
2)在上述4-硝基水杨酸异丙酯中直接加入80mL二氯甲烷溶解,加入1.64g O-甲基硫代磷酰二氯,充分搅拌,加入3mL三乙胺,室温搅拌4h,停止反应,加入100mL水,补加100mL二氯甲烷萃取,有机相加60mL饱和食盐水震荡、洗涤,浓缩蒸干,上硅胶柱,用二氯甲烷和甲醇体积比为10:1的混合溶剂洗脱分离,得到4-硝基水杨酸异丙酯硫磷;
3)在上述4-硝基水杨酸异丙酯硫磷中直接加入100mL二氯乙烷溶解,在搅拌下通入氨气,室温反应2h,停止反应,加水50mL×3,洗涤3次,有机相浓缩蒸干,得到硝基水胺硫磷;
4)在上述硝基水胺硫磷中直接加入100mL甲醇溶解,加入0.5g润湿的钯-碳,排尽空气,通入氢气,室温搅拌2h,停止反应,抽滤,蒸干,上硅胶柱,用二氯甲烷和甲醇体积比为5:1的混合溶剂洗脱分离,得到水胺硫磷半抗原。
实施例2
一种水胺硫磷人工抗原的制备方法,步骤如下:
取实施例1制备的水胺硫磷半抗原113mg,加乙醇1mL溶解,加水2mL、1mol/L HCl1.2mL充分溶解,冷却至0~5℃,加1mL含亚硝酸钠25mg的水溶液,持续搅拌1h,得到半抗原活化液A液;取牛血清白蛋白(BSA)500mg,加0.1mol/L CB缓冲液7mL溶解,冷却至0~5℃,滴加全部的A液,立刻变成红色溶液,继续反应2h,用0.02mol/L PB缓冲液透析纯化3天,每天换液3次,离心,分装,得到与牛血清白蛋白偶联的水胺硫磷人工抗原,分装,-20℃保存。
实施例3
一种水胺硫磷人工抗原的制备方法,步骤如下:
取实施例1制备的水胺硫磷半抗原67mg,加乙醇1mL溶解,加水2mL、1mol/L HCl0.87mL充分溶解,冷却至0~5℃,加1mL含亚硝酸钠15.2mg的水溶液,持续搅拌1h,得到半抗原活化液A液;取卵清蛋白(OVA)500mg,加0.1mol/L CB缓冲液8mL溶解,冷却至0~5℃,滴加全部的A液,立刻变成红色溶液,继续反应2h,用0.02mol/L PB缓冲液透析纯化3天,每天换液3次,离心,分装,得到与卵清蛋白偶联的水胺硫磷人工抗原,分装,-20℃保存。
实施例4
一种水胺硫磷抗体,其制备方法为:
1.动物免疫
取健康的6~8周雌性Balb/c小鼠10只(分为A与B两组,每组5只),初次免疫用弗氏完全佐剂乳化后颈背部皮下多点注射,每只小鼠免疫剂量为200μg与牛血清白蛋白偶联的水胺硫磷人工抗原;之后加强免疫每两周颈背部皮下多点注射一次,乳化用弗氏不完全佐剂;最后一次免疫使用生理盐水代替弗氏不完全佐剂,采用腹腔注射,注射剂量和前面几次相同。具体免疫步骤见表1。
表1小鼠免疫程序
第三次、四次、加强免疫后7d,对小鼠断尾取血,ELISA方法测定小鼠血清效价,具体步骤如下:
(1)用0.05mol/L pH9.6的碳酸盐缓冲液将与卵清蛋白偶联的水胺硫磷人工抗原做1:1000稀释,每孔100μL包被酶标板,37℃孵育2h,甩掉包被液,以PBST洗涤1次,拍干;
(2)每孔加入150μL封闭液,37℃反应2h后倾去封闭液,拍干;
(3)每孔加入50μL以PBS倍比稀释的抗血清,25℃反应30min后倾去反应液,以PBST洗涤3~5次,每次间隔30s,拍干;
(4)加PBS稀释的辣根过氧化物酶标记的羊抗鼠抗抗体(1:1000)100μL/孔,25℃反应30min,以PBST洗涤3~5次,每次间隔30s,拍干;
(5)每孔加入底物显色液A液和B液各50μL,25℃避光反应15min,每孔加入50μL2mol/L的H2SO4溶液终止反应;
(6)酶标仪测定波长在450nm的OD值,以样品孔OD450接近于1的稀释倍数作为阳性血清的效价。
2.细胞融合
(1)饲养细胞制备:断颈处死8~10周龄Balb/c小鼠,浸泡在75%酒精中5min,随即放入超净工作台内,腹部朝上放于平皿内或固定于解剖板上。用眼科镊子夹起小鼠腹部皮肤,用剪刀剪一小口,注意切勿剪破腹膜,以免腹腔液外流和污染。然后用剪刀向上下两侧做钝性分离,充分暴露腹膜。用酒精棉球擦拭腹膜消毒。用注射器吸取5mL RPMI-1640基础培养液,注入小鼠腹腔,轻轻抽回注射器,晃动小鼠腿部和尾部几次。用原注射器抽回腹腔内液体,注入离心管。如此反复操作3~4次。1000r/min离心10min,弃上清。用20~50mL完全培养液重悬细胞,100μL/孔滴加到培养板,置培养箱备用。
(2)脾细胞制备:加强免疫后3d,取免疫Balb/c小鼠,眼眶采血后脱臼处死,在75%酒精中消毒后取脾脏,去除结缔组织,制备脾细胞悬液,转移到50mL离心管中,加RPMI-1640至30mL,1500~2000r/min离心5min,弃上清,加RPMI-1640至30mL,计数待用。
(3)骨髓瘤细胞制备:取3瓶生长状态良好的(活细胞数>95%)骨髓瘤细胞,将之完全吹下,转移到50mL离心管中,加RPMI-1640至30mL,1500~2000r/min离心5min,弃上清,加RPMI-1640至30mL,计数待用。
(4)细胞混合:脾细胞:骨髓瘤细胞=8:1,混合,1500~2000r/min离心5min。
(5)细胞融合:将混合好的细胞离心,倒干上清,把沉淀细胞块弹成糊状,置37℃水浴,在1min内加入1mL融合剂,融合剂为聚乙二醇(PEG)4000,作用2min,并轻轻搅拌细胞,在随后4min内加入20mL无血清的PEG营养液,1000r/min离心10min,弃上清。用20~50mL完全培养液重悬细胞,铺种于含饲养细胞的96孔细胞培养板,每孔100μL,置培养箱中。
3.细胞株筛选
待细胞长至孔底的1/3~1/2时,即可进行抗体检测。采用ELISA方法对有杂交瘤细胞生长的培养孔进行筛选,筛选分两步:第一步先用间接ELISA筛选出阳性细胞孔,第二步选用水胺硫磷为标准品,用间接竞争ELISA对阳性细胞进行抑制效果测定。选出对水胺硫磷标准品具有较好抑制的孔,采用有限稀释法进行亚克隆,用同样的方法进行检测。重复三次,即可得到能稳定分泌水胺硫磷单克隆抗体的细胞株。
4.腹水制备
将液体石蜡注射6~8周Balb/c小鼠,500μL/只。10天后将处于对数生长期的杂交瘤细胞用RPMI-1640基础培养基收集,用血球计数板和显微镜计数,细胞浓度在1.0×106~1.5×106个/mL范围内。每只小鼠0.5mL杂交瘤细胞注射到腹腔。注意观察在一周后小鼠腹部膨大,用无菌注射器于小鼠腹腔采集腹水,每隔一到两天采集一次,这样多次反复采集直到小鼠自然死亡。4℃下5000r/min离心5min,收集上清,并去掉腹水上层漂浮的脂肪和蛋白质膜。
5.抗体纯化
单克隆抗体采用辛酸-硫酸铵方法纯化。
6.抗体效价测定
采用间接ELISA方法测定抗体效价,步骤参考1.中动物免疫的血清效价测定。结果显示,水胺硫磷单克隆抗体的效价≥100000。
7.抗体交叉反应性测定
采用间接竞争ELISA方法测定,结果发现,水胺硫磷单克隆抗体对水胺硫磷及其他有机磷杀虫剂的交叉反应率为:水胺硫磷为100%,甲拌磷、对硫磷、甲基对硫磷、杀螟硫磷、辛硫磷、毒死蜱、甲基毒死蜱、倍硫磷、丙溴磷均<1%。由此可见,所制备的抗体特异性较好。
以上所述实施例仅表达了本发明的实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制,但凡采用等同替换或等效变换的形式所获得的技术方案,均应落在本发明的保护范围之内。
Claims (10)
2.如权利要求1所述的水胺硫磷半抗原的制备方法,其特征在于,包括如下步骤:
1)在催化剂存在下,将4-硝基水杨酸和异丙醇进行酯化反应,纯化后得到4-硝基水杨酸异丙酯;
2)在催化剂存在和碱性条件下,将4-硝基水杨酸异丙酯和O-甲基硫代磷酰二氯进行缩合反应,纯化后得到4-硝基水杨酸异丙酯硫磷;
3)将4-硝基水杨酸异丙酯硫磷和氨气进行氨化反应,纯化后得到硝基水胺硫磷;
4)在催化剂存在下,将硝基水胺硫磷和氢气进行还原反应,纯化后得到水胺硫磷半抗原。
3.如权利要求2所述的水胺硫磷半抗原的制备方法,其特征在于,所述步骤1)包括如下步骤:取4-硝基水杨酸1.83g,加入20mL异丙醇溶解,充分搅拌,加入0.5mL浓硫酸,室温搅拌3h,停止反应,加入200mL水,再加入100mL乙酸乙酯萃取,有机相加100mL水震荡、洗涤,浓缩蒸干,得到4-硝基水杨酸异丙酯。
4.如权利要求2所述的水胺硫磷半抗原的制备方法,其特征在于,所述步骤2)包括如下步骤:在4-硝基水杨酸异丙酯中直接加入80mL二氯甲烷溶解,加入1.64g O-甲基硫代磷酰二氯,充分搅拌,加入3mL三乙胺,室温搅拌4h,停止反应,加入100mL水,补加100mL二氯甲烷萃取,有机相加60mL饱和食盐水震荡、洗涤,浓缩蒸干,上硅胶柱,用二氯甲烷和甲醇体积比为10:1的混合溶剂洗脱分离,得到4-硝基水杨酸异丙酯硫磷。
5.如权利要求2所述的水胺硫磷半抗原的制备方法,其特征在于,所述步骤3)包括如下步骤:在4-硝基水杨酸异丙酯硫磷中直接加入100mL二氯乙烷溶解,在搅拌下通入氨气,室温反应2h,停止反应,加水50mL×3,洗涤3次,有机相浓缩蒸干,得到硝基水胺硫磷。
6.如权利要求2所述的水胺硫磷半抗原的制备方法,其特征在于,所述步骤4)包括如下步骤:在硝基水胺硫磷中直接加入100mL甲醇溶解,加入0.5g润湿的钯-碳,排尽空气,通入氢气,室温搅拌2h,停止反应,抽滤,蒸干,上硅胶柱,用二氯甲烷和甲醇体积比为5:1的混合溶剂洗脱分离,得到水胺硫磷半抗原。
7.一种水胺硫磷人工抗原,其特征在于,其是载体蛋白和权利要求1所述的水胺硫磷半抗原偶联得到的偶联物。
8.如权利要求7所述的水胺硫磷人工抗原,其特征在于,所述载体蛋白为牛血清白蛋白、卵清蛋白、人血清白蛋白或血蓝蛋白。
9.一种水胺硫磷抗体,其特征在于,它是由权利要求7所述的水胺硫磷人工抗原经动物免疫得到,其能与水胺硫磷发生特异性免疫反应。
10.一种权利要求9所述的水胺硫磷抗体在检测水胺硫磷残留中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011285140.XA CN112480167B (zh) | 2020-11-17 | 2020-11-17 | 水胺硫磷半抗原、人工抗原和抗体及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011285140.XA CN112480167B (zh) | 2020-11-17 | 2020-11-17 | 水胺硫磷半抗原、人工抗原和抗体及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112480167A CN112480167A (zh) | 2021-03-12 |
CN112480167B true CN112480167B (zh) | 2022-07-08 |
Family
ID=74930932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011285140.XA Active CN112480167B (zh) | 2020-11-17 | 2020-11-17 | 水胺硫磷半抗原、人工抗原和抗体及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112480167B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115925740B (zh) * | 2023-01-09 | 2023-06-02 | 中国中医科学院医学实验中心 | 甲基异柳磷半抗原、完全抗原、抗体及制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103288872A (zh) * | 2012-03-03 | 2013-09-11 | 北京勤邦生物技术有限公司 | 甲基对硫磷半抗原及其制备方法和应用 |
CN107389927A (zh) * | 2017-08-29 | 2017-11-24 | 联合益康(北京)生物科技有限公司 | 一种检测丙溴磷的时间分辨荧光试纸条及其应用 |
CN110498766A (zh) * | 2019-08-26 | 2019-11-26 | 北京勤邦生物技术有限公司 | 氟啶胺半抗原、人工抗原和抗体及其制备方法和应用 |
CN110627726A (zh) * | 2019-09-23 | 2019-12-31 | 北京勤邦生物技术有限公司 | 咪鲜胺半抗原、人工抗原和抗体及其制备方法和应用 |
CN111269262A (zh) * | 2020-03-03 | 2020-06-12 | 北京勤邦生物技术有限公司 | 丙溴磷半抗原、人工抗原和抗体及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2517930A (en) * | 2013-09-04 | 2015-03-11 | Univ Sheffield | Analogues |
-
2020
- 2020-11-17 CN CN202011285140.XA patent/CN112480167B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103288872A (zh) * | 2012-03-03 | 2013-09-11 | 北京勤邦生物技术有限公司 | 甲基对硫磷半抗原及其制备方法和应用 |
CN107389927A (zh) * | 2017-08-29 | 2017-11-24 | 联合益康(北京)生物科技有限公司 | 一种检测丙溴磷的时间分辨荧光试纸条及其应用 |
CN110498766A (zh) * | 2019-08-26 | 2019-11-26 | 北京勤邦生物技术有限公司 | 氟啶胺半抗原、人工抗原和抗体及其制备方法和应用 |
CN110627726A (zh) * | 2019-09-23 | 2019-12-31 | 北京勤邦生物技术有限公司 | 咪鲜胺半抗原、人工抗原和抗体及其制备方法和应用 |
CN111269262A (zh) * | 2020-03-03 | 2020-06-12 | 北京勤邦生物技术有限公司 | 丙溴磷半抗原、人工抗原和抗体及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112480167A (zh) | 2021-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110498766B (zh) | 氟啶胺半抗原、人工抗原和抗体及其制备方法和应用 | |
CN111333570B (zh) | 氟吡甲禾灵半抗原、人工抗原和抗体及其制备方法和应用 | |
CN111978304B (zh) | 苯醚甲环唑半抗原、人工抗原和抗体及其制备方法和应用 | |
CN110845444B (zh) | 烯酰吗啉半抗原、人工抗原和抗体及其制备方法和应用 | |
CN110642793A (zh) | 嘧菌酯半抗原、人工抗原和抗体及其制备方法和应用 | |
CN111269262B (zh) | 丙溴磷半抗原、人工抗原和抗体及其制备方法和应用 | |
CN111943882B (zh) | 腐霉利半抗原、人工抗原和抗体及其制备方法和应用 | |
CN110845429A (zh) | 戊唑醇半抗原、人工抗原和抗体及其制备方法和应用 | |
CN110627726B (zh) | 咪鲜胺半抗原、人工抗原和抗体及其制备方法和应用 | |
CN114315722A (zh) | 唑虫酰胺人工半抗原及其抗体的制备与应用 | |
CN111333503A (zh) | 三氯杀螨醇半抗原、人工抗原和抗体及其制备方法和应用 | |
CN113264834A (zh) | 一种冷杉醇半抗原、人工抗原和抗体及其制备方法和应用 | |
CN113024415B (zh) | 氟氯氰菊酯半抗原、人工抗原和抗体及其制备方法和应用 | |
CN112480167B (zh) | 水胺硫磷半抗原、人工抗原和抗体及其制备方法和应用 | |
CN102924601B (zh) | 一种莱克多巴胺单克隆抗体的制备方法 | |
CN110590561B (zh) | 除草醚半抗原、人工抗原和抗体及其制备方法和应用 | |
CN113896758B (zh) | 龙葵素半抗原、人工抗原和抗体及其制备方法和应用 | |
CN111875652B (zh) | 多杀菌素半抗原、人工抗原和抗体及其制备方法和应用 | |
CN111943881B (zh) | 溴虫腈半抗原、人工抗原和抗体及其制备方法和应用 | |
CN111825562B (zh) | 氯丹半抗原、人工抗原和抗体及其制备方法和应用 | |
CN111961002A (zh) | 吡唑醚菌酯半抗原、人工抗原和抗体及其制备方法和应用 | |
CN113527390A (zh) | 泰拉霉素半抗原、人工抗原和抗体及其制备方法和应用 | |
CN111825566B (zh) | 六氯苯半抗原、人工抗原和抗体及其制备方法和应用 | |
CN111690007B (zh) | 二嗪磷半抗原和人工抗原及其制备方法与应用 | |
CN106568962A (zh) | 检测百草枯的时间分辨荧光免疫试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |